NFKBIA (NFKB Inhibitor Alpha): A Master Regulator of NF-κB Signaling in Immunity and Cancer

Explore the NFKBIA gene, its protein product IκBα, associated diseases, expression patterns, mutations, and key pathways.

Gene Information Card

Symbol NFKBIA
Full Name NFKB inhibitor alpha
Gene Type protein coding
Chromosomal Location 14q13.2
NCBI Gene ID 4792 ncbi.nlm.nih.gov/gene/4792
Ensembl ID ENSG00000100906
UniProt ID P25963
OMIM ID 164008
HGNC ID 7797
Aliases IKBA, MAD-3, NFKBI

Description

The NFKBIA gene encodes the protein IκBα (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha), a member of the IκB family. IκBα is a key cytoplasmic inhibitor of the NF-κB transcription factor complex. In unstimulated cells, IκBα binds to NF-κB dimers (typically p50/p65) and sequesters them in the cytoplasm, preventing their nuclear translocation and DNA binding. Upon stimulation by various signals (e.g., cytokines, pathogens, stress), IκBα is phosphorylated by the IKK complex, ubiquitinated, and degraded by the proteasome, allowing NF-κB to enter the nucleus and activate transcription of target genes involved in immune response, inflammation, cell survival, and proliferation. Thus, NFKBIA is a critical negative regulator of NF-κB signaling.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Anhidrotic ectodermal dysplasia with T-cell immunodeficiency (EDA-ID) Loss-of-function mutations in NFKBIA impair IκBα function, leading to constitutive NF-κB activation. This disrupts normal development of ectodermal tissues and immune cell function, particularly T-cell responses. OMIM #612132; ClinVar; PMID: 17952090
Infections (severe, recurrent) Impaired NF-κB regulation due to NFKBIA mutations leads to defective immune responses, increasing susceptibility to bacterial, viral, and fungal infections. OMIM #612132; ClinVar
Hepatocellular carcinoma NFKBIA promoter methylation or loss of expression leads to increased NF-κB activity, promoting tumor cell proliferation and survival. COSMIC; PMID: 26576653
Breast cancer Altered NFKBIA expression (often reduced) contributes to constitutive NF-κB activation, associated with tumor progression and poor prognosis. COSMIC; PMID: 21779547
Hodgkin lymphoma NFKBIA mutations or deletions can lead to constitutive NF-κB activation, a hallmark of Hodgkin/Reed-Sternberg cells. COSMIC; PMID: 19531561
Melanoma Loss of NFKBIA expression or function enhances NF-κB signaling, promoting tumor invasion and metastasis. COSMIC; PMID: 17699744

Expression Profile

Tissue Expression
Tissue nTPM level
Whole blood 12.9 Medium
Lymph node 11.8 Medium
Spleen 10.5 Medium
Bone marrow 9.8 Medium
Lung 8.7 Low
Liver 7.2 Low
Brain 6.5 Low
Heart 5.9 Low
Cell Line Expression
Cell Line nTPM Notes
HeLa (cervical cancer) 15.2 High expression; NF-κB pathway active
K-562 (leukemia) 13.4 High expression; involved in immune signaling
A549 (lung cancer) 10.1 Moderate expression
MCF7 (breast cancer) 8.9 Moderate expression
HepG2 (liver cancer) 7.8 Low expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
p.Ser32Ile (c.95G>T) Missense Rare (germline) Loss of phosphorylation site, preventing IκBα degradation and leading to constitutive NF-κB activation; associated with EDA-ID.
p.Ser36Ile (c.107G>T) Missense Rare (germline) Similar to Ser32Ile; impairs signal-induced degradation.
p.Trp11Ter (c.33G>A) Nonsense Rare (germline) Truncated protein, loss of function; causes EDA-ID.
c.94_96del (p.Ser32del) Deletion Rare (somatic) In-frame deletion of Ser32, affecting phosphorylation; seen in some cancers.
c.89A>G (p.Tyr30Cys) Missense Somatic (rare) Alters IκBα structure, possibly affecting binding to NF-κB; reported in lymphoma.
Promoter methylation Epigenetic Frequent in cancers Silences NFKBIA expression, leading to increased NF-κB activity; observed in hepatocellular carcinoma and others.
Mutation functional classification

Loss of Function (LOF)

Loss-of-function mutations (e.g., nonsense, frameshift, or promoter methylation) reduce or abolish IκBα protein expression or its ability to inhibit NF-κB, leading to constitutive NF-κB activation. This is oncogenic in many cancers and causes immunodeficiency in germline cases.

Gain of Function (GOF)

Gain-of-function mutations are rare and not well-documented. Some missense mutations might stabilize IκBα, leading to excessive inhibition of NF-κB, but such variants are not clinically characterized.

Dominant Negative (DN)

Certain missense mutations (e.g., Ser32Ile) act in a dominant-negative manner: the mutant IκBα cannot be phosphorylated and degraded, thus sequestering NF-κB in the cytoplasm even upon stimulation, but also interfering with the function of the wild-type allele in heterozygous state.

Gene Ontology (GO)

• protein binding • NF-kappaB binding
• ubiquitin protein ligase binding • signal transducer activity
• cytoplasm • nucleus
• cytosol • I-kappaB/NF-kappaB complex
• negative regulation of NF-kappaB transcription factor activity • regulation of inflammatory response
• immune response • apoptotic process
• response to lipopolysaccharide

Pathways

• NF-kappaB signaling pathway
• Toll-like receptor signaling pathway
• TNF signaling pathway
• B cell receptor signaling pathway
• T cell receptor signaling pathway
• Cytokine-cytokine receptor interaction
• Apoptosis
• Inflammatory mediator regulation of TRP channels

Protein Summary

IκBα (UniProt P25963) is a 317-amino acid protein with ankyrin repeat domains that mediate binding to NF-κB dimers. It contains N-terminal regulatory serines (Ser32 and Ser36) that are phosphorylated by IKK, and a C-terminal PEST domain involved in constitutive degradation. IκBα shuttles between nucleus and cytoplasm, but predominantly retains NF-κB in the cytoplasm. Its degradation is a key step in NF-κB activation. Mutations affecting its phosphorylation or degradation lead to dysregulated NF-κB signaling, with pathological consequences.

Related Products

Product name Cat.No. Species Gene ID
NFKBIA Knockout HeLa Cell Line EDJ-KQ18993 Human 4792 Details Get a Quote
NFKBIA Knockout HCT 116 Cell Line EDJ-KQ18992 Human 4792 Details Get a Quote
NFKBIA Knockout A-549 Cell Line EDJ-KQ18991 Human 4792 Details Get a Quote
NFKBIA Knockout HEK293 Cell Line EDJ-KQ580 Human 4792 Details Get a Quote

Biological Process

Gene Expression and Regulation: A Complete Technical Map from Mechanism to Validated Cell Models

Promoters, Enhancers and 3D Genome Organization: How to Validate Regulatory Relationships with Editing and Interference Tools

Enhancer–Gene Pair Validation: A Complete Technical Roadmap from Candidate Element to Publishable Evidence

CRISPR Deletion vs CRISPRi for Regulatory Elements: Choosing by Evidence Requirement

Building Reporter Cell Lines for Quantitative Regulatory Readouts

TAD Boundaries and Insulators: What They Constrain and What They Do Not Prove

Super-Enhancers and Cell Identity: Design Strategies for Functional Validation

Validating Transcription Factor Binding Sites: From ChIP Peaks to Functional Evidence

From GWAS Signal to Causal Variant: Functional Validation of Non-Coding Risk Loci

Enhancer Redundancy and Shadow Enhancers: Designing Controls That Catch Compensation

Core Promoter Elements: Dissecting Initiator, TATA and CpG-Island Promoters

Single-Cell Multi-Omics for Mapping Regulatory Elements in Heterogeneous Tissues

How Many Candidate Enhancers Can a Single CRISPRi Screen Test?

What Fragment Size Should Be Deleted When Removing an Enhancer?

How to Design sgRNAs for Enhancer Deletion

What Effect Size Counts as Biologically Meaningful in Enhancer Studies?

What Controls Are Required for a Regulatory Element Knockout?

How to Confirm a TAD Boundary Is Functional

Can ATAC-seq Alone Identify Functional Enhancers?

What Is a Shadow Enhancer, and Why Does It Break Your Screen?

How to Report Negative Results in Regulatory Element Studies

Distance Window or TAD Boundary: Which Constraint Matters More?

DNA Methylation, Histone Marks and Chromatin State: Selecting and Validating Epigenome-Editing Tools

CRISPRoff, dCas9-TET and dCas9-p300: A Practical Comparison for Targeted Epigenetic Editing

How Long Does Epigenetic Silencing Last? Stability, Inheritance and Reversibility

DNMT and TET Knockout Cell Lines: What Phenotypes to Expect and How to Verify Them

Reading Chromatin Accessibility: From ATAC-seq Peaks to Functional Hypotheses

Histone Modification Writers, Readers and Erasers: A Knockout Map

Assessing Off-Target Effects in Epigenetic Editing

Single-Cell Epigenomics: scATAC-seq and scChIP-seq in Development and Disease

Spatial Epigenomics: Mapping Modifications In Situ

Epigenetic Clocks and cfDNA Methylation as Biomarkers

Imprinting and Parent-of-Origin Expression: Why Allele-Specific Regulation Matters

What Is CRISPRoff and How Does It Differ From dCas9-KRAB?

How Stable Is Epigenetic Silencing Across Cell Divisions?

Which Cell Line Is Best for Studying DNA Methylation?

How to Validate a DNMT1 Knockout Clone

What Is a Differentially Methylated Region (DMR)?

Do Epigenetic Edits Create Off-Target Methylation Changes?

How to Link ATAC-seq Changes to Gene Expression Causality

What Is Histone Lactylation and Why Does It Matter?

How to Design a Single-Cell ATAC-seq Experiment

Can Epigenetic Editing Restore a Silenced Gene?

lncRNA, miRNA and RNA Modification: A Complete Path from Function Prediction to Phenotype Validation

Why lncRNA Knockouts Often Show No Phenotype — and How to Design Around It

lncRNA Functional Validation: Knockout vs Knockdown vs Antisense Oligonucleotides

m6A Writers, Readers and Erasers: Mapping and Testing RNA Modification Function

miRNA–Target Validation: Evidence Beyond Luciferase Reporter Assays

RNA-Binding Protein Screens: Design, Readouts and Hit Prioritization

Alternative Splicing Regulation: Isoform-Level Validation Strategies

Circular RNA Biology: Detection, Function and Experimental Pitfalls

RNA Localization and the Spatial Regulation of Translation

Why Does an lncRNA Knockout Often Show No Phenotype?

Knockdown vs Knockout for lncRNA: Which Is More Informative?

How Long a Fragment Should Be Deleted for an lncRNA Knockout?

Which m6A Antibody Should I Use for MeRIP-seq?

What Is the Difference Between RIP-seq and CLIP-seq?

How to Validate a miRNA Target Without a Luciferase Assay

How Many Isoforms Must an Alternative Splicing Study Cover?

Is Circular RNA Detection Reliable Across Platforms?

How to Verify RNA Localization Experimentally

What Proportion of Annotated lncRNAs Are Functional?

CRISPR Knockout, Knock-In, Activation and Screening: A Strategy Matrix for Regulatory Research

Knockout, CRISPRi or Base Editing? A Six-Dimension Decision Matrix

Genome-Wide CRISPR Screening: Library Coverage, MOI and Readout Design

Perturb-seq and Single-Cell Screens: Linking Perturbation to Transcriptional Programs

Essential Genes and Lethal Phenotypes: How to Study What You Cannot Knock Out

Base Editing and Prime Editing in Regulatory Research: When Precision Beats Deletion

Quantifying Editing Efficiency and Off-Target Events: A Practical Framework

Choosing a Cas9 Variant and Delivery Format for Your Cell Type

Multiplex Editing and Temporal Control of Gene Regulation

How Much Library Coverage Is Enough for a Genome-Wide Screen?

What MOI Should I Use for a Lentiviral CRISPR Library?

How to Screen a Non-Proliferative Phenotype

How to Study an Essential Gene with CRISPR

What Is the Difference Between Base Editing and Prime Editing?

How to Measure Knockout Efficiency in a Cell Pool

How to Design a Multiplex Knockout Experiment

Which Cas9 Variant Works Best for AAV Delivery?

What Is a Safe-Harbor Locus for Knock-In?

How Many Clones Must Be Screened to Confirm a Homozygous Knockout?

From Pathway to Model: Validation Paradigms in Cancer, Neuro, Immune and Metabolic Research

Oncogene Dependency and Synthetic Lethality: Building the Right Validation Model

Enhancer Dysregulation in Neurodegeneration: Lessons from Glial and Neuronal Models

CAR-T and ADCC Target Validation: Engineering Immune Cell Lines for Functional Assays

Hippo, WNT and PI3K: Validating Pathway Nodes with Knockout Cell Lines

Drug Target Validation: A Standardized Workflow from Hit to Model

Metabolic Pathway Enzymes: Building Loss-of-Function Models

Gene Editing in iPSC and Organoids: Constraints, Timelines and Readouts

Disease-Associated Non-Coding Variants: From Risk Locus to Cellular Phenotype

How to Validate Pathway Activation After a Knockout

How Long Does iPSC Gene Editing Take?

How to Edit Organoids Without Disrupting Their Structure

Which Cell Line Models ADCC Most Reliably?

How to Build a Synthetic Lethality Screen

What Is a Good Model for Enhancer Dysregulation in Neurons?

How to Validate a Drug Target Before Committing to a Programme

Why Does My Knockout Cell Line Lose the Phenotype After Passaging?

How to Choose Between Human and Mouse Cell Models

What QC Documentation Should Accompany a Custom Cell Line?

Gene Knockout Feasibility Self-Assessment: Ten Constraints That Decide the Project

Pathway-to-Model Reference Chart: Key Genes × Recommended Cell Models

Working with Hard-to-Transfect Cells: A Delivery Strategy Guide

How We Validate Knockout Clones: PCR, Sanger and Western Blot in Combination

Custom Knockout Cell Line Service: Strategy Design, Single-Cell Cloning and Triple Validation

Stable dCas9-KRAB and Cas9 Expression Cell Lines

Knock-In Reporter Cell Lines for Regulatory Readouts

Genome-Wide CRISPR Library Screening Service

Services Comparison: In-House vs CRO vs Off-the-Shelf Cell Lines

Epigenetic Editing Enters the Clinic: What It Means for Research Models

AI Sequence Models in Regulatory Genomics: Hype, Reality and Where They Help

Live-Cell Imaging Rewrites the Rules of Transcriptional Regulation

Spatial and Single-Cell Multi-Omics: The Next Validation Frontier

From CRISPR Screens to Programmable Medicine: A Five-Year Outlook

Contact Us
*
*
*
How did you hear about us: